This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Walgreens Boots' Retail Pharmacy Strong, Competition Rife
by Zacks Equity Research
Walgreens Boots (WBA) rides high on continued prescription growth and strength in the Retail Pharmacy USA division.
PetMed (PETS) Q3 Earnings Top Estimates, Reorder Sales Solid
by Zacks Equity Research
The upside in third-quarter fiscal 2018 sales at PetMed (PETS) is a result of the significant increase in new orders and reorder sales.
What to Expect From Quest Diagnostics (DGX) in Q4 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.
Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?
by Zacks Equity Research
Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.
Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.
Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.
Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.
Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.
Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Key Factors to Influence PerkinElmer's (PKI) Q4 Earnings
by Zacks Equity Research
PerkinElmer (PKI) solid product portfolio, positive market trends and acquisition are likely to drive earnings in the fourth quarter.
CVS Health Grows in PBM With Rheumatoid Arthritis Program
by Zacks Equity Research
The new Transform Rheumatoid Arthritis Care program to help CVS Health (CVS) provide a personalized whole-patient support through specialty pharmacy and embedded AccordantCare nurses.
Positive Market Trends Aid Cardiovascular Systems Amid Woes
by Zacks Equity Research
Cardiovascular Systems (CSII) firmly stands to gain from several favorable trends existing in the PAD and CAD market spaces.
Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG
by Zacks Equity Research
Medtronic (MDT) makes efforts to boost RTG business.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.
BD's CE Mark and Check-Point's Screening Test to Fight CPO
by Zacks Equity Research
BD (BDX)-Check-Points' advanced bacterial screening assay will help lower mortality rates caused by AMR.
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?
by Zacks Equity Research
ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.
Medtronic (MDT) Wins FDA Nod for New Clinician Programmer
by Zacks Equity Research
Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.
5 Reasons Why You Should Offload Wright Medical Stock Now
by Zacks Equity Research
Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).
CVS Health Grows on Pharmacy Services, Retail Remains a Drag
by Zacks Equity Research
CVS Health's (CVS) strong Pharmacy Services business continues to gain from a sturdy Specialty Pharmacy. However, its highly competitive retail pharmacy business raises concern.